Study of ARO-APOC3 in Adults With Dyslipidemia
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 418 participants.
Also called NCT05413135
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 418 participants
- Sponsor
- Registry
-
NCT05413135
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States, Australia, Canada, Hungary, Netherlands, New Zealand, Poland
- Registry status
- Completed
Technical summary
Registry record NCT05413135. Allocation not applicable; no masking; primary purpose treatment. Start 2022-07-07 (actual); primary completion 2025-09-22 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study of ARO-APOC3 in Adults With Dyslipidemia
- Condition
- Dyslipidemias
- Intervention (Drug)
- ARO-APOC3
- Lead sponsor
- Arrowhead Pharmaceuticals
Record details
- Record id
cardio:ct-nct05413135- Content hash
eb642da9b7dcde3b4f5d9eee41b6b7ac908b4912e170d447d350df171aefa30f